NIH Considers Exclusive License for Cysteamine Cancer Treatment

Summary

The National Institutes of Health is considering granting an exclusive commercialization license to use cysteamine for the treatment of pancreatic, breast, and hepatocellular cancer. The license would cover patents filed in the US, Canada, South Korea, Australia, and Mexico for the use of cysteamine to suppress tumor metastases.